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Diabetic ketoacidosis without  
hyperglycemia as a complication  
of SGLT2 inhibitors treatment
ABSTRACT
SGLT2 inhibitors (gliflozins) are a new group of hypo-
glycemic drugs which have been available on the mar-
ket for the past four years. They inhibit the reabsorp-
tion of glucose in the proximal renal tubules, reduce 
the renal glucose threshold and increase glycosuria, 
thereby lowering blood glucose levels. Clinical recom-
mendations of the Polish Diabetes Association mention 
the possibility of using gliflozins both as monotherapy 
in patients with type 2 diabetes, as well as in combina-
tion with other hypoglycemic drugs, including insulin. 
Databases of adverse events of SGLT2 inhibitors indi-
cate an increased risk of diabetic ketoacidosis without 
significant hyperglycemia. An unusual course of this 
form of acidosis makes the complication difficult to 
diagnose. This paper describes a possible pathogenic 
process of ketoacidosis without hyperglycemia. The 
fact that this complication was observed mainly in 
patients with prolonged type 2 diabetes (including pa-
tients treated with insulin) and in patients with type 1 
diabetes who used the drug “off-label”, implies that 
insulin deficiency may be a pathogenic factor in this 
disorder. Another important factor was insufficient 
carbohydrate intake associated with reduced food 
consumption due to illness or accompanying disorders. 
At the same time, in most cases, a decrease in insulin 
dose stemming from low blood glucose levels was 
observed. The study highlighted the precautions and 
prevention methods for ketoacidosis without hyper-
glycemia in patients treated with SGLT2 inhibitors, as 
well as proper and rapid diagnosis of this complication. 
(Clin Diabet 2016; 5, 2: 66–72)
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Introduction
Diabetes is currently classified into the heteroge-
neous group of metabolic diseases characterized by 
hyperglycemia. It stems from a defect in insulin pro-
duction and/or function. It is one of the most common 
chronic diseases in the modern society. Currently there 
are 415 million people with diabetes around the world. 
It is estimated that this number will reach around 642 
million in 2040. Over 90% of people with the disease 
have type 2 diabetes [1].
Despite an asymptomatic or oligosymptomatic 
course, type 2 diabetes is not a mild disease. Effects of 
longlasting diabetes include dysfunction, damage and 
insufficiency of multiple organs. Each year the disease 
causes 5 million deaths. Diabetes is also the main cause 
of myocardial infarctions, cerebral strokes, amputa-
tions, renal insufficiency and blindness. Diagnosed in 
middle age, it shortens the average lifespan by 5–10 
years compared to the general population [2–4].
The main clinical challenge of modern diabetology 
is optimizing and increasing effectiveness of treatment 
for type 2 diabetes. Despite employing various classes 
of drugs directed at pathogenic mechanisms of diabe-
tes, such as insulin resistance and dysfunctions in insulin 
secretion, the effects of treatment remain unsatisfac-
tory. Recently, kidneys have become the target organ for 
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one of the classes of drugs which reduce blood glucose 
level. Kidneys play a vital role in regulating glucose 
concentration by utilizing glucose for metabolic needs, 
gluconeogenesis, glucose filtration and reabsorption of 
approximately 180 g of glucose per day [5–7].
Sodium-glucose cotransporter 2 inhibitors
Sodium-dependent glucose transporters (SGLT) 
belong to the great family of transmembrane proteins 
and are responsible for intestinal glucose absorption 
and renal glucose reabsorption. So far, six isoforms of 
these cotransporters have been described, although 
most likely the most important functions among them 
are performed by two: SGLT1 and SGLT2 [5].
The SGLT1 protein is a glucose and galactose trans-
port system and is characterized by high affinity and 
low capacity. It is mostly found in brush border cells 
in the small intestine and is responsible for absorbing 
glucose/galactose in food. This transporter can also 
be found in the S3 segment of nephron’s proximal 
tubules, in the brain, in the skeletal muscles and the 
cardiac muscle, in the liver and in the lungs. The SGLT2 
sodium-glucose cotransporter can be found almost 
exclusively only in the brush border of the S1 segment 
of nephron’s proximal tubule [6]. It is characterized by 
low affinity, but high capacity in respect to glucose. 
SGLT2 is responsible for reabsorption of 90% of glu-
cose in the primary filtrate. The remaining glucose is 
reabsorbed by SGLT1.
Historically, the first SGLT cotransporters inhibitor 
was phlorizin, discovered in 1835. It was isolated from 
apple tree bark. Due to its bitter taste, similar to that 
of willow tree or cinchona tree extracts, it was thought 
that it would have similar properties and was initially 
used as a medicine for fever and infectious diseases, 
including malaria. Fifty years later it was found that 
large amounts of phlorizin cause glycosuria [8]. Being 
a non-specific SGLT1 and SGLT2 inhibitor, phlorizin 
found no use in treatment of diabetes since it caused 
severe gastrointestinal symptoms linked to its impedi-
ment of intestinal glucose absorption due to it blocking 
SGLT1. Furthermore, it was poorly absorbed from the 
gastrointestinal tract.
Modern synthetic analogs of phlorizin have con-
siderable selectivity in respect to SGLT2 and so do not 
cause any gastrointestinal side effects.
Currently, three SGLT2 inhibitors (so-called glifloz-
ins) have been approved by the European Medicines 
Agency (EMA) for marketing in the European Union, 
and by the Food and Drug Administration (FDA) in the 
United States.
In Europe, dapagliflozin (Forxiga, AstraZeneca) [9] 
was the first to be introduced in November 2012. In 
November 2013, canagliflozin (Invokana, Janssen) [10] 
was introduced. The youngest, empagliflozin, was ap-
proved in the European Union in May 2014 (Jardiance, 
Boehringer Ingelheim) [11].
In the United States, canagliflozin (Invokana, Jans-
sen) [12] was the first to be introduced in March 2013. 
Dapagliflozin (Farxiga, AstraZeneca) was approved for 
marketing in January 2014 [13]. Empagliflozin (Jardi-
ance, Boehringer Ingelheim) has been present on the 
American market since August 2014 [14].
Combination preparations containing SGLT2 in-
hibitors are also available. These are combinations of 
dapagliflozin with metformin (Xigduo, AstraZeneca), 
canagliflozin with metformin (Vokanamet, Janssen) and 
empagliflozin with metformin (Synjardy, Boehringer 
Ingelheim), available in both Europe and the United 
States. In the United States, a product which is a com-
bination of empagliflozin and linagliptin (Glyxambi, 
Boehringer Ingelheim) has also been introduced.
Further drugs from the SGLT2 inhibitors category 
are in various phases of pre-registration research. In 
Japan, ipragliflozin, tofogliflozin and luseogliflozin 
are available.
All SGLT2 inhibitors can be used as monotherapy 
in patients with type 2 diabetes where diet and exer-
cise alone do not provide satisfactory control of blood 
glucose level and metformin cannot be administered 
for various reasons. This class of drugs can be used in 
combination therapy with other hypoglycemic drugs, 
including insulin [15].
Hypoglycemic action of this class of drugs does not 
depend on preserved residual function of pancreatic β 
cells. SGLT2 inhibitors, by impeding glucose reabsorp-
tion in renal proximal tubules, decrease renal glucose 
threshold and increase glycosuria [16–18]. The amount 
of glucose removed by the kidneys depends on the 
blood glucose concentration and glomerular filtration 
rate (GFR). Inhibiting SGLT2 effectively reduces glucose 
concentration in the serum, while retaining SGLT1 activ-
ity prevents hypoglycemia. An increased level of SGLT2 
mRNA was found in the cells isolated from proximal 
tubules of patients with type 2 diabetes compared to 
healthy people [19]. However, SGLT2 inhibitors only 
block reabsorption of approximately 30–50% of glucose 
excreted into primary urine [20].
The benefits of using SGLT2 inhibitors are not 
limited only to improvement in the balance of carbohy-
drate metabolism parameters. An important advantage 
of these drugs is their contribution to body weight 
loss and reduction in blood pressure while being used 
[21–24].
Results of research on effectiveness and safety of 
empagliflozin were presented in October 2015 during 
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an EASD meeting in Stockholm and published in New 
England Journal of Medicine. During the EMPA-REG 
trial, adding empagliflozin to the current standard 
treatment for patients with type 2 diabetes with high 
risk of cardiovascular events reduced the risk of those 
events, including death from cardiovascular causes, 
non-fatal myocardial infarctions and non-fatal cerebral 
strokes, by 14%. Furthermore, treatment using empa-
gliflozin resulted in lower death rates from any cause 
(32% reduction) and fewer hospitalizations for heart 
failure (35% reduction) [25].
The most common side effects connected with 
this drug class stem from the basic mechanism of their 
action: glycosuria promotes more frequent infections 
of the genitourinary system, particularly infections of 
fungal etiology. Since SGLT2 inhibitors constitute a new 
drug class, the long-term safety of their administration 
requires further research and observations. There is an 
increasing number of reports of increased risk of ke-
toacidosis or severe urinary tract infections, including 
urosepsis [26–29].
SGLT2 inhibitors and ketoacidosis
On 15 May 2015 the FDA in the US, whose pur-
pose is to control and approve drugs for marketing, 
issued, based on an analysis of the FDA Adverse Event 
Reporting System (FAERS) database, a communication 
warning about the increased risk of ketoacidosis with 
low or mild increase in blood glucose concentration 
(euglycemic diabetic ketoacidosis — euDKA) con-
nected with taking the SGLT2 inhibitors registered so 
far. Between March 2013 to 6 June 2014, 20 cases of 
ketoacidosis or ketosis were identified in patients with 
diabetes treated using this drug class. All cases required 
hospitalization. They were mostly patients with type 2 
diabetes; a few cases concerned patients with type 1 
diabetes. In several reports, the type of diabetes the 
person taking the SGLT2 inhibitor had was not speci-
fied [27].
A month later, EMA in Europe informed that, until 
19 May 2015, 147 cases of ketoacidosis in patients with 
diabetes treated using SGLT2 inhibitors were registered 
in the EudraVigilance database [28]. 101 cases con-
cerned type 2 diabetes, while 46 cases were reported 
in patients with type 1 diabetes who used the SGLT2 
inhibitor “off-label” (Tab. 1).
Of these 147 people with reported cases of ketoaci-
dosis, 96 used canagliflozin, 46 used dapagliflozin and 
5 used empagliflozin. All the cases were serious and 69 
required hospitalization. Time to onset of ketoacidosis 
following inclusion of gliflozin varied between 3 days 
to 1 year. Most episodes occurred during the first two 
months of treatment.
In another notice, issued 4 December 2015, the 
FDA recommended adding warnings about increased 
risk of ketoacidosis and serious urinary tract infections 
while taking this class of drugs to labels of SGLT2 in-
hibitors [27]. Simultaneously, it was announced that, 
on the basis of an analysis of FAERS reports, between 
March 2013 (approval of first gliflozin) and May 2015 
73 cases of ketoacidosis were identified in patients 
taking SGLT2 inhibitors. 48 patients used canagliflozin, 
21 used dapagliflozin and 4 used empagliflozin. In all 
cases patients were either hospitalized or had to stay 
in the hospital’s emergency department.
Of these 73 cases, 44 reports concerned type 2 
diabetes, while 15 reports concerned patients with type 
1 diabetes who used the SGLT2 inhibitor “off-label”. 
In 13 cases the type of diabetes was not specified, 
however 10 patients were being treated concomitantly 
with other oral antidiabetic drugs, suggesting that they 
had type 2 diabetes as well. One case was reported in 
a patient with a previously undiagnosed LADA type 
diabetes. Of the reports concerning cases with type 2 
diabetes, 34 contained information about possible 
combination treatment with insulin. Concurrent insu-
lin therapy was used for 16 patients. Time to onset of 
ketoacidosis following inclusion or an increase in the 
dose of gliflozin varied between 1 day to 1 year (43 days 
on average). Though considering the number of people 
taking SGLT2 inhibitors (over five hundred thousand 
patients) the number of described complications seems 
small, it was noted that mildly increased blood glucose 
levels combined with developing acidosis may cause 
a delay in diagnosis, and as a consequence a significant 
increase in ketoacidosis.
At the same time, it was announced that 19 cases 
of urosepsis in patients with diabetes treated using 
SGLT2 inhibitors had been registered in the FAERS 
database between March 2013 and October 2014. 
Canagliflozin was used by 10 people, while dapagli-
flozin by 9. No deaths were reported. 4 patients had 
to be admitted to an intensive care unit and 3 had 
to be dialysed due to renal insufficiency. The average 
length of time the drug was being used prior to the 
onset of the infection was 45 days (between 2 and 270 
days). In 15 cases, further administration of SGLT2 was 
discontinued.
Diabetic ketoacidosis  
without hyperglycemia
Clinical picture
Peters et al. presented cases of diabetic ketoaci-
dosis without hyperglycemia in 9 patients, including 
7 with type 1 diabetes and 2 with type 2 diabetes, 
who were taking an SGLT2 inhibitor [30]. All patients 
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were being treated with canagliflozin, which is most 
likely due to the fact that this drug was the first to 
be introduced in the United States and saw the most 
widespread use. No patient had a previous episode of 
diabetic ketoacidosis. Nearly all reported nausea and 
vomiting. It would seem, however, that nausea was a 
consequence of rather than a factor causing acidosis. 
Stomach aches, headaches and dizziness were observed 
in singular cases. Tachypnea and tachycardia were 
observed in one (female) patient who had no gastro-
intestinal symptoms.
In patients with type 1 diabetes, ketoacidosis 
was preceded by infection, consumption of alcohol, 
increased physical activity and/or decreased intake of 
carbohydrates, often in conjunction with a decrease 
in the dose of insulin or discontinuation of its use. In 
patients with type 2 diabetes, ketoacidosis occurred 
soon after surgery.
The patients described had normal or slightly 
elevated blood glucose levels, which resulted in a 
significant delay in diagnosis of ketoacidosis and con-
sequently in administration of appropriate treatment 
(Tab. 2). However, once the diagnosis was made, the 
patients’ condition rapidly improved after including 
liquids and insulin, administered intravenously. In sev-
eral cases, a recurrence of ketoacidosis was observed 
after resuming administration of the SGLT2 inhibitor.
Pathophysiology
Diabetic ketoacidosis is a complex disorder in 
carbohydrate, fat and protein metabolism as well as 
water-electrolyte and acid-base balance, stemming 
from profound insulin deficiency. It is a severe metabolic 
complication which may occur during the course of any 
type of diabetes. It typically happens in patients with 
type 1 diabetes, less often in those with type 2 diabetes.
Diabetic ketoacidosis is a consequence of a signifi-
cant deficiency or lack of insulin accompanied by an 
increased concentration of insulin-counteracting hor-
mones, such as glucagon, cortisol, catecholamines or 
growth hormone. Insulin deficiency, through decreased 
glucose uptake in insulin-dependent tissues and in-
creased production of glucose via gluconeogenesis 
and glycogenolysis, leads to hyperglycemia. Lipolysis 
results in an excess of free fatty acids and glycerol. Free 
fatty acids undergo re-esterification into triglycerides 
and b-oxidation, which leads to increased ketogenesis 
in the liver. Overproduction of ketone bodies causes 
development of metabolic acidosis. Catabolic state is 
complemented by increased proteolysis. Catabolism of 
proteins leads to the creation of amino acids, which 
provide substrate for glucose production (gluconeo-
genesis). Hyperglycemia and ketonemia activate the 
mechanisms of osmotic diuresis. Loss of water leads 
to dehydration and electrolyte disorders. This results 
in hyperosmolarity of the blood plasma and impairs 
blood perfusion in organs. Free water and electrolyte 
deficit, augmented by vomiting and rapid breathing 
as well as increasing acid-base imbalance, leads to 
disruptions in the functioning of the central nervous 
system and coma.
Laboratory diagnostic criteria for diabetic ketoaci-
dosis include: hiperglycemia > 250 mg/dl (13.9 mmol/L), 
though the values are usually much higher, up to 600–
–800 mg/dL or more; pH of arterial or capillary blood 
< 7.3; bicarbonate serum concentration < 15 mmol/L; 
presence of ketone bodies in urine or serum; increased 
anion gap > 12 mmol/L [15].
Diabetic ketoacidosis does not always cause in-
creased blood glucose levels. In 1973 Munro et al. 
presented 211 cases of ketoacidosis, of which 37 were 
described as euglycemic ketoacidosis, defined as blood 
glucose concentration < 300 mg/dL (16.7 mmol/L) and 
bicarbonate serum concentration £ 10 mEq/L [31]. 
These cases concerned young people with type 1 dia-
betes, of which 2/3 were women. The primary cause 
of acidosis developing in the patients was decreased 
carbohydrate intake due to vomiting or starvation, oc-
Table 1. Cases of ketoacidosis in patients with diabetes 
taking SGLT2 inhibitors, registered in the EudraVigilance 
database until 19 May 2015
Name  
of drug
Patients  
with type 2  
diabetes
Patients  
with type 1  
diabetes
Cases reported 
in the European 
Union
Dapagliflozin 34 12 18
Canagliflozin 63 33 0
Empagliflozin 4 1 0
Table 2. Results of laboratory tests of patients taking an 
SGLT2 inhibitor in whom ketoacidosis without hypergly-
cemia was diagnosed, as described by Peters et al.
Parameters tested Patients with 
type 2  
diabetes 
(n = 2)
Patients with 
type 1  
diabetes 
(n = 7)
Glycemia [mg/dL] 150–169 96–233
pH 7.12 6.9–7.15
Anion gap [mEq/L] 16–19 17–35
Bicarbonates [mmol/L] 5–10 6–18
Ketones in blood or urine High  
concentration
High  
concentration
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casionally coupled with reduced insulin dose. In later 
years it was accepted that serum glucose concentration 
in euglycemic ketoacidosis is ≤ 200 mg/dl (11,1 mmol/l) 
[32, 33]. However, it is not a value which could be de-
fined as normoglycemia. Hence the name “ketoacidosis 
without hyperglycemia” seems more appropriate.
The fact that cases of ketoacidosis without hyper-
glycemia while taking SGLT2 inhibitors were reported 
mostly in patients with prolonged diabetes, including 
those treated using insulin and those with type 1 dia-
betes, indicates that insulin deficiency is an important 
pathogenic factor in this disorder. At the same time, 
in most cases there was a decrease in the insulin dose 
administered so far due to low blood glucose levels. 
In some patients, a significant reduction in blood 
glucose levels was likely only the effect of increased 
urinary glucose excretion promoted by SGLT2 inhibi-
tors. In addition, in many of them blood glucose levels 
decreased also as a result of reduced appetite, nausea, 
sometimes vomiting or refraining from eating due to 
surgery. Consumption of alcohol on the day preceding 
the onset of the ailment may have also been one of the 
causes of reduced blood glucose levels. Regardless of 
reason, lower blood glucose levels led to a decrease in 
the administered insulin doses, and in case of type 2 
diabetes to reduced secretion of endogenous insulin.
Urinary glucose excretion while taking SGLT2 
inhibitors is approx. 50–100 g/day. In overweight or 
obese patients, who consume 50% of their daily re-
quirement as carbohydrates, such level of excretion 
constitutes approx. 17–34% of carbohydrate intake 
for men and 22–44% for women. In people who are 
not significantly overweight, urinary glucose excretion 
equals approx. 50% of daily carbohydrate intake, for 
both men and women [34]. The amount of glucose 
available for metabolic processes in tissues is reduced, 
especially since there is a concurrent decrease in circu-
lating endogenous insulin or exogenous insulin dos-
age. Lower insulin concentration leads to a significant 
increase in glucagon concentration in the serum. This 
stems from the fact that insulin’s inhibitory, paracrine 
effect on a-cells is diminished, and possibly also from 
reduced glucose transport to these cells due to SGLT2 
inhibition [35, 36].
Lower blood glucose levels and insulin concentra-
tion with a simultaneous increase in glucagon levels 
lead to reduced glucose influx into cells, reduced 
glycolysis and increased lipolysis and b-oxidation of 
free fatty acids. This, in turn, causes an increased rate 
of synthesis of ketone bodies in the liver. The increase 
in glucagon concentration may also be stimulated 
through hypovolemia and orthostatic hypotension, 
which may happen during the first three months of 
SGLT2 treatment and are a result of increased diuresis 
and consequently hypovolemia. Concentrations of 
cortisol and catecholamines, which also take part in 
intensifying lipolysis processes (Fig. 1), may also rise 
at this time for the same reasons.
Perhaps in some cases the described sequence of 
metabolic disorders is sufficient for minor ketoacidosis 
to occur; it exhibits such symptoms as malaise, reduced 
appetite, nausea, vomiting or headache. Since at the 
same time blood glucose levels remain relatively low, 
patients do not suspect the possibility of this complica-
tion and decide to decrease or skip their insulin dose. 
The result is further increase in acidosis and severe 
deterioration of the patient’s state of health.
In some patients, described metabolic disorders 
may be caused by a situation leading to limited meal 
consumption, including carbohydrates, e.g. dieting, 
starvation, preparing for a medical examination, stom-
ach aches, surgery or other, sometimes insignificant 
disorders causing reduced appetite. The amount of 
available glucose, already lowered through glycosuria 
caused by SGLT2 inhibitors, is further reduced, causing 
the whole sequence of disorders described above. In 
this case it will also ultimately lead to ketoacidosis with 
normoglycemia or slight hyperglycemia.
Safety and prevention methods
On 16 February 2016, the Pharmacovigilance Risk 
Assessment Committee (PRAC) of the European Medi-
cines Agency published recommendations meant to 
minimize the risk of ketoacidosis in patients undergoing 
treatment using SGLT2 inhibitors [37]. Patients taking 
any such drugs should be aware of the symptoms of 
ketoacidosis, including body weight loss, nausea or 
vomiting, stomach aches, excessive thirst, rapid and 
deep breathing, confusion, unusual sleepiness or fa-
tigue, sweet-smelling breath, sweet or metallic taste 
in the mouth or change in urine or sweat odour. It is 
worth to inform the patient about the need to monitor 
ketonuria and/or ketonemia, despite “good” blood glu-
cose levels, in situations promoting ketogenesis: during 
another disease, during periods of reduced food and 
fluid intake, after reducing insulin doses, if nausea and/ 
/or vomiting occur, after alcohol consumption. Further-
more, PRAC recommends to temporarily cease SGLT2 
inhibitor treatment in patients during perioperative 
period or hospitalized due to severe illness.
Summary
Available hypoglycemic drugs often do not make 
it possible to attain therapy goals or their effectiveness 
is reduced due to side effects. Currently, research to 
find new therapy options with a different mechanism 
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of action is being conducted on a large scale. SGLT2 
inhibitors (gliflozins), which impede renal glucose reab-
sorption, constitute a new drug class. Their mechanism 
of action is not dependent on b cells functioning or 
insulin sensitivity. They improve the control of blood 
glucose levels in patients with type 2 diabetes, both 
when used as monotherapy as well as in combination 
therapy with other hypoglycemic drugs or insulin.
Gliflozins have been available on the market for 
4 years. Databases of adverse effects indicate the 
possibility of diabetic ketoacidosis in patients taking 
them. An unusual course of this type of ketoacidosis, 
with normal or relatively low glucose concentration, 
makes it potentially difficult to diagnose. Though the 
risk of this type of ketoacidosis occurring in patients 
with type 2 diabetes while taking SGLT2 inhibitors 
seems very low, it is nevertheless worth to be aware 
of such a complication. The risk may increase during 
periods of reduced meal consumption, starvation (e.g. 
in perioperative period), other diseases which increase 
the need for insulin, stress or in patients with prolonged 
diabetes, in whom the dysfunction of b cells is greater.
Should symptoms which may conform to ketoaci-
dosis occur, the basic diagnostic method, possible to 
perform even at home, ought to be testing for ketone 
bodies in urine or in blood. Such a test should be per-
formed even if there is no significant hyperglycemia. 
The presence of ketones should be a signal to ingest 
carbohydrates, apply insulin and increase the amount 
of fluids taken, while simultaneously ceasing to take 
the drug. If the symptoms are mild, such action may be 
sufficient to correct metabolic disorders and halt the 
Figure 1. Possible pathogenic mechanisms of ketoacidosis without hyperglycemia while taking SGLT2 inhibitors
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ailment. General malaise and exacerbation of symptoms 
indicate a need for hospital treatment. It is important, 
in case clinical symptoms conforming to ketoacidosis 
occur in patients taking SGLT2 inhibitors, regardless of 
type of diabetes, to remember about the possibility of 
this complication, even if blood glucose levels are within 
normal range or only slightly elevated. Laboratory 
diagnosis is simple, as is treatment, if applied in time.
If diabetic ketoacidosis is suspected or confirmed, 
gliflozin treatment should be ceased immediately and 
not resumed, unless a different cause of acidosis is 
determined.
The safety of long-term administration of drugs 
from this class requires further research.
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